An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms.
OBJECTIVE
Our purpose was to evaluate the use of transvaginal ultrasonography for the detection of endometrial disease in a population of postmenopausal women who were without symptoms.


METHODS
Postmenopausal women were screened for potential inclusion in 2 multicenter, double-blind, placebo-controlled studies of 2 years' duration to evaluate the safety and efficacy of idoxifene in the prevention of osteoporosis. Baseline endometrial evaluation was performed by transvaginal ultrasonography and aspiration biopsy of the endometrium.


RESULTS
A total of 1926 women were screened by transvaginal ultrasonography, and 1833 of them had endometrial thickness < or =6 mm. Five cases of endometrial abnormality (adenocarcinoma [n = 1] and atypical hyperplasia [n = 4]) were detected in the 1750 women from this cohort who underwent biopsy. The negative predictive value was >99%. One case of adenocarcinoma was detected in the 42 women who had endometrial thickness >6 mm and underwent biopsy. However, the sampling rate (45%) of women with endometrial thickness >6 mm was too low for confidence in the positive predictive value of 2%.


CONCLUSIONS
Despite a high negative predictive value, transvaginal ultrasonography may not be an effective screening procedure for detection of endometrial abnormality in untreated postmenopausal women who are without symptoms.
Fleischer
A C
AC
Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Wheeler
J E
JE
Lindsay
I
I
Hendrix
S L
SL
Grabill
S
S
Kravitz
B
B
MacDonald
B
B
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000473:pathology; D001707:Biopsy, Needle; D004311:Double-Blind Method; D004714:Endometrial Hyperplasia / Q000000981:diagnostic imaging / Q000473:pathology; D016889:Endometrial Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology; D004717:Endometrium / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D010919:Placebos; D017698:Postmenopause; D012680:Sensitivity and Specificity; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014463:Ultrasonography; D014591:Uterine Diseases / Q000000981:diagnostic imaging*
D010919:Placebos; D013629:Tamoxifen; C071362:idoxifene